|
(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID
|
DB06921 |
|
|
Eribaxaban
|
DB06920 |
|
|
N-{2-[(4'-CYANO-1,1'-BIPHENYL-4-YL)OXY]ETHYL}-N'-HYDROXY-N-METHYLUREA
|
DB06971 |
|
|
2-CHLORO-N-(3-CYANO-5,6-DIHYDRO-4H-CYCLOPENTA[B]THIOPHEN-2-YL)-5-DIETHYLSULFAMOYL-BENZAMIDE
|
DB06970 |
|
|
Nα-[(2S)-2-{[(S)-[(1S)-1-{[(Benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl]methyl}-5-phenylpentanoyl]-L-tryptophanamide
|
DB04318 |
|
|
NTx-265
|
DB05649 |
[NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause of death worldwide. In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. It is also investigating use of the compound for neurodegenerative disorders, such as Huntington’s disease and Alzheimer’s disease.
] |
|
D-[(N-Hydroxyamino)Carbonyl]Phenylalanine
|
DB04316 |
|
|
5-(dodecylthio)-1H-1,2,3-triazole-4-carboxylic acid
|
DB06979 |
|
|
3,3-Dichloro-2-Phosphonomethyl-Acrylic Acid
|
DB04317 |
|
|
N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]-4-methoxybenzohydrazide
|
DB06978 |
|
|
1-Methylcytosine
|
DB04314 |
|
|
(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine
|
DB06977 |
|
|
Guanosine-5'-Diphosphate
|
DB04315 |
[A guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem]] |
|
Larazotide
|
DB05645 |
[An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.] |
|
1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
|
DB06976 |
|
|
KP-1461
|
DB05644 |
[KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.] |
|
2,3-Difluorobenzyl Alcohol
|
DB04312 |
|
|
(3S)-3-methyl-D-aspartic acid
|
DB04313 |
|
|
5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin-3(2H)-one
|
DB06974 |
|
|
DDP-225
|
DB05642 |
[DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases. Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003.] |
